

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

ring bonds :

1-6 1-11 2-3 2-11 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :

1-6 1-11 2-3 2-11 3-4 4-5

normalized bonds :

5-6 5-7 6-10 7-8 8-9 9-10

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom

10/655,364

=> d his

(FILE 'HOME' ENTERED AT 15:42:01 ON 08 FEB 2006)

FILE 'REGISTRY' ENTERED AT 15:42:09 ON 08 FEB 2006

L1 STRUCTURE UPLOADED

L2 2 S L1

L3 STRUCTURE UPLOADED

L4 1 S L3

L5 41 S L3 SSS FUL


FILE 'CAPLUS' ENTERED AT 15:43:28 ON 08 FEB 2006

L6 4 S L5

=> d l3

L3 HAS NO ANSWERS

L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> d ibib abs hitstr total

L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:203177 CAPLUS  
 DOCUMENT NUMBER: 140:235731  
 TITLE: Preparation of cinnolines and their use as  
 beta-lactamase inhibitors and antibacterial agents  
 INVENTOR(S): Musicki, Branislav  
 PATENT ASSIGNEE(S): Aventis Pharma SA, Fr.  
 SOURCE: Fr. Demande, 67 pp.  
 CODEN: FRXXBL  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2844273	A1	20040312	FR 2002-10957	20020905
WO 2004022563	A1	20040318	WO 2003-FR2639	20030904
W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, RO, SC, SG, SY, TN, TT, UA, UZ, VC, VN, YU, ZA RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004097490	A1	20040520	US 2003-655364	20030904
EP 1537117	A1	20050608	EP 2003-769564	20030904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006501258	T2	20060112	JP 2004-533566	20030904
PRIORITY APPLN. INFO.:			FR 2002-10957	A 20020905
			WO 2003-FR2639	W 20030904
OTHER SOURCE(S):		MARPAT 140:235731		
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [wherein Y = (CH<sub>2</sub>)<sub>n</sub>; n = 1 or 2; R<sub>1</sub> = H, alkyl, (CH<sub>2</sub>)<sub>m</sub>R';  
 m = 0 or 1; R' = heteroaryl/aryl; R<sub>2</sub> = H, halo, alkyl, OH and derivs.,  
 NO<sub>2</sub>, alkylaminocarbonyl/alkylsulfonyl/alkylcarbonylmonoalkyl/dialkyl/amino  
 , alkylaminocarbonyl, alkylaminosulfonyl, CO<sub>2</sub>H and derivs., CN,  
 alkylsulfonyloxy, alkylcarbonyl, alkyl; X = -C(:O)-N(OH)- and derivs.]  
 were prepared as beta-lactamase inhibitors and antibacterial agents. For  
 example, II was prepared by cyclization of 2-acetylaniline in the presence  
 of NaNO<sub>2</sub>/HCl, oxidation of cinnolinol, mono-Boc protection at the 2-position,  
 oximation of cinnolinone with O-(allyl)hydroxyamine, reduction of the  
 O-alkylated oxime, Boc-deprotection, and cyclization of III•2HCl with  
 diphosgene in the presence of MeCN/TEA/DMAP. Selected I were able to  
 inhibit either TEM-1 (enzyme from Escherichia coli) and P99 (enzyme from  
 E. Cloacae) with IC<sub>50</sub> values in the range of 0.012 mM to 0.57 mM and 0.015  
 to 0.46 mM, resp., when tested in competition expts. using nitrocefin as  
 the reporter substrate. I were tested against two Gram-pos. bacteria as  
 well as four Gram-neg. bacteria. Thus, I are and their compns. with  
 β-lactam antibiotics, are useful as beta-lactamase inhibitors and

antibacterial agents.


IT **667467-63-2P 667467-74-5P, 2-Propenyl**  
 [(3-oxo-2,3,4,5-tetrahydro-2,5-methano-1H-1,2,4-benzotriazepin-4-yl)oxy]acetate **667467-79-0P 667467-82-5P**  
**667467-85-8P 667467-88-1P 667467-91-6P**  
**667467-92-7P 667467-93-8P 667468-03-3P**  
**667468-04-4P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(antibacterial agent; preparation of cinnolines as beta-lactamase inhibitors and anti-bacterial agents)


RN 667467-63-2 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepin-3(1H)-one, 4,5-dihydro-4-(2-propenyloxy)- (9CI) (CA INDEX NAME)




RN 667467-74-5 CAPLUS

CN Acetic acid, [(1,5-dihydro-3-oxo-2,5-methano-2H-1,2,4-benzotriazepin-4(3H)-yl)oxy]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 667467-79-0 CAPLUS

CN Acetic acid, [[1,5-dihydro-1-(methylsulfonyl)-3-oxo-2,5-methano-2H-1,2,4-benzotriazepin-4(3H)-yl]oxy]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 667467-82-5 CAPLUS

CN Acetic acid, [[1-[(benzoylamino)carbonyl]-1,5-dihydro-3-oxo-2,5-methano-2H-1,2,4-benzotriazepin-4(3H)-yl]oxy]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 667467-85-8 CAPLUS

CN Acetic acid, [[1,5-dihydro-3-oxo-1-[(phenylsulfonyl)amino]carbonyl]-2,5-methano-2H-1,2,4-benzotriazepin-4(3H)-yl]oxy]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 667467-88-1 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepine-1-acetic acid, 1,3,4,5-tetrahydro- $\alpha$ ,3-dioxo-4-[2-oxo-2-(2-propenyloxy)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 667467-91-6 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepine-1-acetic acid, 1,3,4,5-tetrahydro-3-oxo-4-(2-propenyloxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 667467-92-7 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepin-3(1H)-one, 4,5-dihydro-1-methyl-4-(2-propenyloxy)- (9CI) (CA INDEX NAME)




RN 667467-93-8 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepin-3(1H)-one, 4,5-dihydro-4-(2-propenyloxy)-1-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 667468-03-3 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepine-1-acetic acid, 1,3,4,5-tetrahydro-3-oxo-4-(2-propenyloxy)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 667468-04-4 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepine-1-acetic acid, 1,3,4,5-tetrahydro-3-oxo-4-(2-propenyloxy)- (9CI) (CA INDEX NAME)



IT 667467-70-1P 667467-80-3P 667467-81-4P  
 667467-83-6P 667467-84-7P 667467-86-9P  
 667467-87-0P 667467-89-2P 667467-90-5P  
 667467-94-9P 667467-95-0P 667467-96-1P  
 667467-97-2P 667467-98-3P 667467-99-4P  
 667468-00-0P 667468-01-1P 667468-02-2P

667468-05-5P 667468-06-6P 667468-07-7P


667468-08-8P 667468-09-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antibacterial agent; preparation of cinnolines as beta-lactamase inhibitors and anti-bacterial agents)


RN 667467-70-1 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepin-3(1H)-one, 4,5-dihydro-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 667467-80-3 CAPLUS

CN Acetic acid, [[1,5-dihydro-1-(methylsulfonyl)-3-oxo-2,5-methano-2H-1,2,4-benzotriazepin-4(3H)-yl]oxy]- (9CI) (CA INDEX NAME)



RN 667467-81-4 CAPLUS


CN Acetic acid, [[1,5-dihydro-1-(methylsulfonyl)-3-oxo-2,5-methano-2H-1,2,4-benzotriazepin-4(3H)-yl]oxy]-, compd. with N-(1-methylethyl)-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 667467-80-3

CMF C12 H13 N3 O6 S





CM 2


CRN 108-18-9

CMF C6 H15 N

i-Pr-NH-Pr-i

RN 667467-83-6 CAPLUS

CN Acetic acid, [[1-[(benzoylamino)carbonyl]-1,5-dihydro-3-oxo-2,5-methano-2H-1,2,4-benzotriazepin-4(3H)-yl]oxy]- (9CI) (CA INDEX NAME)



2


RN 667467-84-7 CAPLUS

CN Acetic acid, [[1-[(benzoylamino)carbonyl]-1,5-dihydro-3-oxo-2,5-methano-2H-1,2,4-benzotriazepin-4(3H)-yl]oxy]-, compd. with N-(1-methylethyl)-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 667467-83-6

CMF C19 H16 N4 O6



CM 2


CRN 108-18-9

CMF C6 H15 N

i-Pr-NH-Pr-i

RN 667467-86-9 CAPLUS

CN Acetic acid, [[1,5-dihydro-3-oxo-1-[[ (phenylsulfonyl) amino] carbonyl]-2,5-methano-2H-1,2,4-benzotriazepin-4(3H)-yl]oxy]- (9CI) (CA INDEX NAME)



3


RN 667467-87-0 CAPLUS

CN Acetic acid, [[1,5-dihydro-3-oxo-1-[[ (phenylsulfonyl) amino] carbonyl]-2,5-methano-2H-1,2,4-benzotriazepin-4(3H)-yl]oxy]-, compd. with N-(1-methylethyl)-2-propanamine (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 667467-86-9

CMF C18 H16 N4 O7 S



CM 2


CRN 108-18-9

CMF C6 H15 N

i-Pr-NH-Pr-i

RN 667467-89-2 CAPLUS

CN Acetic acid, [(1,5-dihydro-3-oxo-2,5-methano-2H-1,2,4-benzotriazepin-4(3H)-yl)oxy]- (9CI) (CA INDEX NAME)



4


RN 667467-90-5 CAPLUS

CN Acetic acid, [(1,5-dihydro-3-oxo-2,5-methano-2H-1,2,4-benzotriazepin-4(3H)-yl)oxy]-, compd. with N-(1-methylethyl)-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 667467-89-2

CMF C11 H11 N3 O4



CM 2


CRN 108-18-9

CMF C6 H15 N

i-Pr-NH-Pr-i

RN 667467-94-9 CAPLUS


CN 2,5-Methano-2H-1,2,4-benzotriazepine-1-carboxamide, 1,3,4,5-tetrahydro-3-oxo-N-(phenylsulfonyl)-4-(2-propenyloxy)- (9CI) (CA INDEX NAME)



7


RN 667467-95-0 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepine-1-carboxamide, N-benzoyl-1,3,4,5-tetrahydro-3-oxo-4-(2-propenyloxy)- (9CI) (CA INDEX NAME)




8

RN 667467-96-1 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepine-1-acetic acid, 1,3,4,5-tetrahydro- $\alpha$ ,3-dioxo-4-(2-propenyloxy)-, ethyl ester (9CI) (CA INDEX NAME)


RN 667467-97-2 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepine-1-sulfonamide, 1,3,4,5-tetrahydro-N-methyl-3-oxo-4-(2-propenyloxy)- (9CI) (CA INDEX NAME)




RN 667467-98-3 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepine-1-carbothioamide, 1,3,4,5-tetrahydro-3-oxo-N-phenyl-4-(2-propenyloxy)- (9CI) (CA INDEX NAME)




RN 667467-99-4 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepin-3(1H)-one, 4,5-dihydro-1-(methylsulfonyl)-4-(2-propenyloxy)- (9CI) (CA INDEX NAME)




RN 667468-00-0 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepine-1-carboxamide, 1,3,4,5-tetrahydro-3-oxo-4-(2-propenyloxy)- (9CI) (CA INDEX NAME)




RN 667468-01-1 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepine-1-carboxamide, 1,3,4,5-tetrahydro-3-oxo-N-(phenylmethyl)-4-(2-propenyloxy)- (9CI) (CA INDEX NAME)




RN 667468-02-2 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepin-3(1H)-one, 4,5-dihydro-1-(phenylmethyl)-4-(2-propenyloxy)- (9CI) (CA INDEX NAME)




RN 667468-05-5 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepine-1-acetamide, 1,3,4,5-tetrahydro-3-oxo-4-(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 667468-06-6 CAPLUS


CN 2,5-Methano-2H-1,2,4-benzotriazepine-1-acetic acid, 1,3,4,5-tetrahydro-3-oxo-4-(sulfoxy)-,  $\alpha$ -ethyl ester, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 667468-07-7 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepin-3(1H)-one, 4,5-dihydro-1-methyl-4-(sulfoxy)-, sodium salt (9CI) (CA INDEX NAME)




5

● Na

RN 667468-08-8 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepin-3(1H)-one, 4,5-dihydro-1-(3-pyridinylmethyl)-4-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 667468-09-9 CAPLUS

CN 2,5-Methano-2H-1,2,4-benzotriazepine-1-acetic acid, 1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-, alpha-ethyl ester (9CI) (CA INDEX NAME)






REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~10~~ ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1990:77053 CAPLUS  
 DOCUMENT NUMBER: 112:77053  
 TITLE: Thermally induced fragmentation and cyclization of  
 C-azidohydrazones  
 AUTHOR(S): Bruche, Luca; Garanti, Luisa; Zecchi, Gaetano  
 CORPORATE SOURCE: Dip. Chim. Org. Ind., Univ. Milan, Milan, 20133, Italy  
 SOURCE: Journal of Heterocyclic Chemistry (1989), 26(3),  
 619-24  
 CODEN: JHTCAD; ISSN: 0022-152X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 112:77053  
 GI




AB C-Azidohydrazones  $\text{RNHN:CR}_1\text{CO}_2\text{R}_2$  (I,  $\text{R} = \text{Ph}$ , 4-MeC<sub>6</sub>H<sub>4</sub>, 3,5-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>, 2,6-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>, 2-MeC<sub>6</sub>H<sub>4</sub>,  $\text{R}_2 = \text{Me}$ ;  $\text{R} = 2\text{-NCC}_6\text{H}_4$ ,  $\text{R}_2 = \text{Et}$ ;  $\text{R}_1 = \text{N}_3$ ) were synthesized from the corresponding C-chlorohydrazones I ( $\text{R}$ ,  $\text{R}_2 = \text{same}$ ;  $\text{R}_1 = \text{Cl}$ ) and submitted to thermal decomposition in boiling C<sub>6</sub>H<sub>6</sub>. Various kinds of products were obtained due to competitive modes of evolution of first-formed nitrenes I ( $\text{R}_1 = \text{N}\bullet$ ), namely H abstraction to form aminohydrazones I ( $\text{R}_1 = \text{NH}_2$ ) and benzotriazepine II and radical fragmentation to give diaryls RPh and arylglyoxylate arylhydrazones  $\text{RNHN:CRCO}_2\text{R}_2$ . Ring-closed products, namely 1,2,4-triazoles III and imidazolones IV were also formed.

IT **125240-53-1P**

RL: FORM (Formation, nonpreparative); PREP (Preparation)  
 (formation of, in thermal decomposition of azidohydrazone)

RN 125240-53-1 CAPLUS

CN 1H-1,2,4-Benzotriazepine-3-carboxylic acid, 2,5-dihydro-9-methyl-, methyl ester (9CI) (CA INDEX NAME)



LS ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1981:75084 CAPLUS

DOCUMENT NUMBER: 94:75084

TITLE: Crystal structure of 1,3-diphenyl-5-carbethoxymethylene-1H-4,5-dihydro-1,2,4-benzotriazepine

AUTHOR(S): Perez-Salazar, A.; Cano, F. H.; Garcia-Blanco, S.

CORPORATE SOURCE: Inst. Quim. Fiz. "Rocasolano", CSIC, Madrid, 6, Spain

SOURCE: Journal of Crystal and Molecular Structure (1980),

Volume Date 1979, 9(6), 317-23

CODEN: JCMLB5; ISSN: 0308-4086

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The title compound is orthorhombic, space group P212121, with a 15.1342(3), b 14.1692(3), and c 9.6533(3) Å; d.(exptl.) = 1.23 and Z = 4. The structure was solved by direct methods and refined to R 0.048 (Rw = 0.068) for 1831 observed reflections. An intramol. H bond is present. The conformation of the 7-membered ring is boatlike with a quasi-mirror plane through N(1).

IT 76553-23-6


RL: PRP (Properties)

(crystal structure of)

RN 76553-23-6 CAPLUS

CN Acetic acid, (1,2-dihydro-1,3-diphenyl-5H-1,2,4-benzotriazepin-5-ylidene)-, ethyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1980:198370 CAPLUS

DOCUMENT NUMBER: 92:198370

TITLE: Studies on 7-membered benzo condensed heterocycles.

6. 5-Oxo-1H-4,5-dihydro-1,2,4-benzotriazepines.

Chemical behavior towards alkylating, acidic and alkaline agents

AUTHOR(S): Bianchi, Mario; Hausermann, Enrico; Rossi, Silvano

CORPORATE SOURCE: Dep. Chem., Roussel Maestretti S.p.A., Milan, 20131, Italy

SOURCE: Journal of Heterocyclic Chemistry (1979), 16(7), 1411-16

CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 92:198370

AB The chemical behavior of 4-methyl- and 4-phenyl-5-oxo-1H-4,5-dihydro-1,2,4-benzotriazepines towards methylating and acidic agents was studied. The 4-Me derivative, when treated with FSO<sub>3</sub>Me furnished, after crystallization from H<sub>2</sub>O, a quaternary salt (2,4-dimethyl-5-oxo-1H-4,5-dihydro-1,2,4-benzotriazepinium fluorosulfonate); from the 4-Ph derivative a complex mixture was obtained, which, after boiling with H<sub>2</sub>O, afforded 2-methylindazolone, PhNH<sub>2</sub>.HO<sub>3</sub>SF and HCO<sub>2</sub>H. In acidic medium the 4-Me derivative isomerized to 1-imino-3-methylquinazolin-4-one, but the 4-Ph derivative exclusively yielded products resulting from ring opening. In alkaline medium, both compds. gave hydrolytic cleavage products.

IT 73647-13-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and reactions of)


RN 73647-13-9 CAPLUS

CN 1H-1,2,4-Benzotriazepinium, 4,5-dihydro-2,4-dimethyl-5-oxo-, fluorosulfate (9CI) (CA INDEX NAME)

CM 1

CRN 73647-12-8

CMF C10 H12 N3 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 15181-47-2

CMF F O3 S

